Catalent, Inc.

Equities

CTLT

US1488061029

Pharmaceuticals

Market Closed - Nyse 04:00:02 2024-03-28 pm EDT 5-day change 1st Jan Change
56.45 USD -0.05% Intraday chart for Catalent, Inc. +1.07% +25.64%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Novo Nordisk hopes to launch experimental obesity drug this decade RE
Transcript : Catalent, Inc. - Special Call
European stocks hover near record highs at start of busy week RE
Wegovy packing supplier Catalent lays off 300 workers RE
Novo Holdings to Invest up to $7 Billion a Year by 2030 MT
Novo Holdings to Invest up to $7 Billion a Year by 2030 MT
Catalent Swings to Fiscal Q2 Adjusted Loss as Revenue Declines MT
Earnings Flash (CTLT) CATALENT Posts Q2 Revenue $1.03B, vs. Street Est of $1.01B MT
Catalent, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI
North American Morning Briefing : Stock Futures Rise; S&P 500 Again Tests 5,000 Milestone DJ
Global markets live: Kering, Publicis, Paypal, Mattel, Nvidia... Our Logo
Astrazeneca says Catalent deal shows importance of in-house capacity RE
European Medicines Agency to Look Into Novo Nordisk's Acquisition of Catalent Sites MT
US FDA finds control lapses at Catalent plant being sold to Novo RE
EU watchdog is looking into availability of drugs made at Catalent sites sold to Novo RE
EU watchdog to assess availability of drugs made at Catalent sites sold to Novo RE
Eli Lilly Calls for Regulatory Scrutiny of Novo Holding's Catalent Deal MT
US Regulator Finds Lapses at Novo Nordisk Supplier Catalent's Factory MT
US FDA finds control lapses at Catalent plant being sold to Novo RE
UBS Downgrades Catalent to Neutral From Buy, Adjusts Price Target to $63.50 From $58 MT
Deutsche Bank Adjusts Price Target on Catalent to $63.50 From $44, Maintains Hold Rating MT
Stephens Downgrades Catalent to Equalweight From Overweight, $63.50 Price Target MT
RBC Downgrades Catalent to Sector Perform From Outperform on Heels of Announced Sale to Novo Holdings, Lifts PT to $63.50 From $58 MT
Sector Update: Health Care Stocks Rise Late Afternoon MT
Wall Street falls with interest rates, earnings in focus RE
Chart Catalent, Inc.
More charts
Catalent, Inc. is specialized in pharmaceutical outsourcing services. The group offers solutions for the development and formulation of drugs, biological products and animal health products. Net sales break down by activity as follows: - provision of development services and clinical supply services (55.4%); - subcontracted manufacturing services (44.6%). Net sales are distributed geographically as follows: the United States (63.2%), Europe (28.7%) and other (8.1%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
12
Last Close Price
56.45 USD
Average target price
63.5 USD
Spread / Average Target
+12.49%
Consensus
  1. Stock
  2. Equities
  3. Stock Catalent, Inc. - Nyse
  4. News Catalent, Inc.
  5. Earnings Flash (CTLT) CATALENT Posts Q3 Revenue $1.27B, vs. Street Est of $1.22B